ARQT: Total Zoryve TRx ~22.9K, Including Foam Zoryve TRx at ~11.8K and 0.15% Cream at ~4.8K for WE July 17, 2026

Research evidence excerpt

ARQT: Total Zoryve TRx ~22.9K, Including Foam Zoryve TRx at ~11.8K and 0.15% Cream at ~4.8K for WE July 17, 2026

echnologies, without the prior written consent of Guggenheim.

Portions of the research contained herein have been generated using artificial intelligence ("AI"). We primarily use AI to gather general market or industry

data and to compile company-specific information to facilitate the recipient's preliminary review. In providing this research, we assume that any information

obtained from public sources, data suppliers (including AI systems) and other third parties is reasonable and reliable but acknowledge that any such

information (including AI content) could contain errors, inconsistencies, bias or outdated or irrelevant information. We seek to update our research as

appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of

reports are published at irregular intervals as appropriate in the research analyst's judgement. Guggenheim Securities conducts a full-service, integrated

investment banking and brokerage business. Guggenheim Securities is a member of SIPC (http://www.sipc.org). Guggenheim Securities' salespeople,

traders, and other professionals may provide oral or written market commentary or trading strategies to Guggenheim Securities' clients and our employees

trading for our own account that reflect opinions that are contrary to the opinions expressed in this research. Guggenheim and certain of our affiliates conduct

an investment management business, trade for their own accounts, and may make investment decisions that are inconsistent with the recommendations

or views expressed in this research.